Clinical characteristics, outcomes and prognosticators in adult patients hospitalized with COVID-19.
Adult
Age Factors
Aged
COVID-19
/ blood
Female
Fibrin Fibrinogen Degradation Products
/ analysis
Hospitalization
/ statistics & numerical data
Humans
L-Lactate Dehydrogenase
/ blood
Male
Middle Aged
Natriuretic Peptide, Brain
/ blood
Odds Ratio
Organ Dysfunction Scores
Procalcitonin
/ blood
Prognosis
Respiration, Artificial
/ mortality
Retrospective Studies
Risk Factors
SARS-CoV-2
Sex Factors
Coronavirus
Hospital epidemiology
SARS CoV-2
Journal
American journal of infection control
ISSN: 1527-3296
Titre abrégé: Am J Infect Control
Pays: United States
ID NLM: 8004854
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
13
05
2020
revised:
03
07
2020
accepted:
04
07
2020
pubmed:
12
7
2020
medline:
5
2
2021
entrez:
12
7
2020
Statut:
ppublish
Résumé
COVID-19 is a novel disease caused by SARS-CoV-2. We conducted a retrospective evaluation of patients admitted with COVID-19 to one site in March 2020. Patients were stratified into 3 groups: survivors who did not receive mechanical ventilation (MV), survivors who received MV, and those who received MV and died during hospitalization. There were 140 hospitalizations; 22 deaths (mortality rate 15.7%), 83 (59%) survived and did not receive MV, 35 (25%) received MV and survived; 18 (12.9%) received MV and died. Thee mean age of each group was 57.8, 55.8 and 72.7 years, respectively (P = .0001). Of those who received MV and died, 61% were male (P = .01). More than half the patients (n = 90, 64%) were African American. First measured d-dimer >575.5 ng/mL, procalcitonin > 0.24 ng/mL, lactate dehydrogenase >445.6 units/L, and brain natriuretic peptide (BNP) >104.75 pg/mL had odds ratios of 10.5, 5, 4.5 and 2.9, respectively for MV (P < .05 for all). Peak BNP >167.5 pg/mL had an odds ratio of 6.7 for inpatient mortality when mechanically ventilated (P = .02). Age and gender may impact outcomes in COVID-19. D-dimer, procalcitonin, lactate dehydrogenase and BNP may serve as early indicators of disease trajectory.
Sections du résumé
BACKGROUND
COVID-19 is a novel disease caused by SARS-CoV-2.
METHODS
We conducted a retrospective evaluation of patients admitted with COVID-19 to one site in March 2020. Patients were stratified into 3 groups: survivors who did not receive mechanical ventilation (MV), survivors who received MV, and those who received MV and died during hospitalization.
RESULTS
There were 140 hospitalizations; 22 deaths (mortality rate 15.7%), 83 (59%) survived and did not receive MV, 35 (25%) received MV and survived; 18 (12.9%) received MV and died. Thee mean age of each group was 57.8, 55.8 and 72.7 years, respectively (P = .0001). Of those who received MV and died, 61% were male (P = .01). More than half the patients (n = 90, 64%) were African American. First measured d-dimer >575.5 ng/mL, procalcitonin > 0.24 ng/mL, lactate dehydrogenase >445.6 units/L, and brain natriuretic peptide (BNP) >104.75 pg/mL had odds ratios of 10.5, 5, 4.5 and 2.9, respectively for MV (P < .05 for all). Peak BNP >167.5 pg/mL had an odds ratio of 6.7 for inpatient mortality when mechanically ventilated (P = .02).
CONCLUSIONS
Age and gender may impact outcomes in COVID-19. D-dimer, procalcitonin, lactate dehydrogenase and BNP may serve as early indicators of disease trajectory.
Identifiants
pubmed: 32652252
pii: S0196-6553(20)30689-1
doi: 10.1016/j.ajic.2020.07.005
pmc: PMC7345482
pii:
doi:
Substances chimiques
Fibrin Fibrinogen Degradation Products
0
Procalcitonin
0
fibrin fragment D
0
Natriuretic Peptide, Brain
114471-18-0
L-Lactate Dehydrogenase
EC 1.1.1.27
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
158-165Informations de copyright
Copyright © 2020 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Nat Methods. 2020 Mar;17(3):352
pubmed: 32094914
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2020 Jul 28;71(15):896-897
pubmed: 32271368
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
Chest. 2020 Jul;158(1):97-105
pubmed: 32304772
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079